For GHK-Cu wound healing, this means explicitly communicating: GHK-Cu is not FDA-approved as a drug for any indication Human wound-healing evidence is limited to small, non-randomized studies The compounding pharmacy source is not subject to the same oversight as FDA-approved manufacturers Alternative, evidence-based wound-healing options exist (negative pressure wound therapy, growth factor therapies like becaplermin, advanced wound dressings) Monitoring will be required, with associated lab costs Document this conversation in the medical record
2021YFC2100300) and the National Natural Science Foundation of China (Grant No
This cascade involves the same fibroblasts and collagen synthesis pathways that GHK-Cu activates
5 Much of the human data on topical GHK-Cu is from studies that do not specify the concentration used, however, generally products have been used in cosmetic preparations at concentrations between 0.2-2%
Key limitations GHK and GHK-Cu are related but chemically distinct
Ayadi, Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study, Altern